Voice of Health

Warren Peters,  MD,  MPH,  FOMADirector – Metabolic Obesity Research Clinic (MORC)Associate Professor LOMA LINDA UNIVERSITY – School of Public Health From Dopamine Pills to Personalized Neurons: Aspen’s Autologous Cell Therapy for Parkinson’s Disease Parkinson’s disease (PD) has long been managed through pharmacology: levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and …

Warren Peters,  MD,  MPH,  FOMADirector – Metabolic Obesity Research Clinic (MORC)Associate ProfessorLOMA LINDA UNIVERSITY – School of Public HealthNutrition Research Center When you care for someone with Alzheimer’s, Parkinson’s, ALS, FTD, or Huntington’s, something quietly devastating happens…you start losing control of your life too.” “They’re losing abilities.You’re losing stability.And every …

Actionable Ways to Build and Maintain Mind-Sharpening Friendships If you’re finding your social circle shrinking, leveraging your passion for digital tools can actually be the key to expanding it: 1. Join Niche Online Groups: Use platforms like Meetup or Facebook to find groups centered around your specific interests, such as …

LRRK2 PROTAC (ARV-102): From Target Degradation to Biomarker-Driven Trials LRRK2 PROTAC (ARV-102): From Target Degradation to Biomarker-Driven Trials Curator: Warren Peters, MD, MPH, FOMA Silo: Voice of Health – Research Edition Research Summary ARV-102 is a proteolysis-targeting chimera (PROTAC) that binds LRRK2 and recruits an E3 ligase, tagging the protein …

A New Approach in Parkinson’s: Removing a Problem Protein (LRRK2) A New Approach in Parkinson’s: Removing a Problem Protein Silo: Voice of Health – Patient Edition What’s Being Studied Scientists are testing a new therapy called ARV-102. It helps cells identify and remove a protein called LRRK2 that may contribute …

Healthspan Is Becoming Real: What the GLP-1 Shift Means Healthspan Is Becoming Real: What the GLP-1 Shift Means At a leading aging research meeting, major drug makers described GLP-1 medicines as “longevity therapeutics.” That language shift matters: it opens the door to earlier prevention trials, better biomarkers, and treatments that …

Healthspan Is Becoming Real: What the GLP-1 Shift Means Healthspan Is Becoming Real: What the GLP-1 Shift Means At a leading aging research meeting, major drug makers described GLP-1 medicines as “longevity therapeutics.” That language shift matters: it opens the door to earlier prevention trials, better biomarkers, and treatments that …

Working Together for Better Alzheimer’s Care: The ADRC Team Approach Working Together for Better Alzheimer’s Care Source: Akter S, Bawa EM, Riccardi N, et al. Journal of Alzheimer’s Disease Reports. 2025;9. doi:10.1177/25424823251385902 Silo: Voice of Health (Patient Edition) Why “Team Science” Matters Alzheimer’s affects memory, independence, and families. No single …

Citation: Athauda D et al., 2025, New England Journal of Medicine, DOI 10.1056/NEJMoa2306791Research Summary:A randomized double-blind Phase 2 trial evaluated lixisenatide, a GLP-1 receptor agonist, in 156 individuals Participants received lixisenatide or placebo over 12 months. The lixisenatide group maintained stable with a decline in the placebo group. Gastrointestinal effects …

Team Science for Dementia: The ADRC Circular Loop (Discovery → Development → Delivery → Dissemination) Harnessing Team Science in Dementia Research: The ADRC Circular Loop Citation: Akter S, Bawa EM, Riccardi N, et al. Journal of Alzheimer’s Disease Reports. 2025;9. doi:10.1177/25424823251385902 Curator: Warren Peters, MD MPH FOMA • Silo: Voice …